The European Commission has granted orphan drug designation to US biotech firm NPS Pharmaceuticals (Nasdaq: NPSP) Natpara (recombinant human parathyroid hormone (rhPTH [1-84]) for the treatment of hypoparathyroidism.
The company's shares advanced 2.1% to $32.39 on Friday morning (January 3). The stock has more than tripled over the past 12 months.
“We are very pleased that Natpara has received orphan drug status in the EU,” said Francois Nader, president and chief executive of NPS Pharmaceuticals. “As a global rare disease biopharmaceutical company, this aligns with our commitment to deliver innovative therapies that transform the lives of patients around the world. Hypoparathyroidism patients face a significant burden of disease given the multitude of physical, cognitive, and emotional symptoms associated with this disorder. Natpara could be the first PTH replacement therapy to treat this condition.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze